The latest induced, embryonic, and other pluripotent stem cell news.
Their Chinese Phase 1 reportedly showed motor improvement in 90% of patients. With that data in hand, the FDA is allowing them to move forward out West.
The Australian biotech company is hoping to tackle aGvHD in Europe, which appears to have twice as many cases as the USA.
Syntax is bringing its Cellgorithm cell-therapy discovery platform to the table, while Mayo Clinic will provide expertise in pancreatic biology and functional testing for preclinical diabetes.
JAX will use the funding to study how a genetic variant affects the disease and potentially standardize and characterize human cell models for broader research.
Published in the Journal of Nanobiotechnology, the iPSC-derived therapy delivers BDNF mRNA to injured spinal tissue, improving motor recovery in preclinical studies.
Building on work at the University of Wisconsin-Madison, the Australian biotech company expects to release data from its Phase 3 iPSC-derived MSC KOA & Phase 2 Graft-vs-Host-Disease trials in the coming months.
The company is working on iPSC-derived, AAV, and small molecule therapies for neurodegenerative, orthopedic, and blood-based disorders, with the help of OpenAI's models which seem to be accelerating life science research.
The site will also serve as the company's new headquarters, expanding its services in iPSC-based drug discovery, regenerative medicine, and cell therapy work.
The partnership hopes to speed up the scalable development of SC451 for type 1 diabetes by standardizing treatment protocols, improving clinical delivery and post-care, and preparing the therapy for broader use across...
Cartherics is developing multiple immune cell therapies for women's health, including its lead candidate, CTH-401, a CAR-NK therapy targeting ovarian cancer.
